China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
Policy / Regulatory
Lei Haichao Takes Over as Party Secretary of China’s National Health Commission
The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
CDE Seeks Public Comment on Latest Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), China’s regulatory body, is currently seeking public feedback on...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics
The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
China’s Q1 2024 Pharma Trade Registers 6.3% Growth Amid Global Recovery
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
China’s National Drug Alliance Procurement Office Announces Insulin VBP Re-Tender Results
The National Drug Alliance Procurement Office in China has published the winning results of the...
China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement
The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...
China’s NHC to Assume Management of Human Genetic Resources from May 2024
The National Health Commission (NHC) of China has announced that the State Council has approved...
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...
China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms
A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign...
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
China’s CDE Issues Guidelines for Pediatric Drug Labeling Updates
China’s Center for Drug Evaluation (CDE) has issued a notice outlining the “Detailed Rules for...